Vor Biopharma Inc. (VOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VOR's 50-day simple moving average crossed above its ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...

On Wednesday, Vor Biopharma VOR hit a noteworthy technical benchmark, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 89, up from 62 the day before.

Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...

Vor Bio (NASDAQ:VOR) shares soared more than 20% in Friday pre-market trading, after it said that it has entered into a securities purchase agreement for a private investment in public equity ...

Vor Bio announces a $55.6 million PIPE to fund clinical trials and expects to report updated data in 2025. Vor Bio, a clinical-stage cell and genome engineering company, announced a securities ...

Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...

H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ:VOR), highlighting the company’s “rebirth” following the in-licensing of telitacicept. On Thursday, the company announced a strategic licensing ...

Baird lowered the firm’s price target on Vor Bio (VOR) to $46 from $64 and keeps an Outperform rating on the shares. The firm updated its model.

Although VOR mostly focused on off-road motorcycles, it migrated to street bikes in 2002, the same year it changed its name to VOR Motorcycles. The VOR EN-E 530 is a big-bore four-stroke that ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vor Biopharma, a clinical-stage cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the ...